BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

524689

PARENTLD

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

PARENTERAL DRUGS (INDIA) LTD. Share Price Update

As of the latest trading session, PARENTERAL DRUGS (INDIA) LTD. share price is currently at ₹ 3.39, which is up by ₹ 0.00 from its previous closing. Today, the stock has fluctuated between ₹ 3.08 and ₹ 3.39. Over the past year, PARENTERAL DRUGS (INDIA) LTD. has achieved a return of -19.47 %. In the last month alone, the return has been 9.70 %. Read More...

PARENTERAL DRUGS (INDIA) LTD. fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    0.0

  • P/E Ratio (TTM)

    0.0

  • Beta

    0.0

  • Book Value / share

    0.0

  • Return on equity

    0.0%

  • EPS (TTM)

    0.0

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    0.0

info icon alternate text

PARENTERAL DRUGS (INDIA) LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2022 (Values in Cr)
Revenue 1.77
Operating Expense 34.81
Net Profit 23.81
Net Profit Margin (%) 1345.19
Earnings Per Share (EPS) 7.99
EBITDA 46.36
Effective Tax Rate (%) -23.94
Particulars DEC 2021 (Values in Cr)
Revenue 1.44
Operating Expense 45.68
Net Profit -34.52
Net Profit Margin (%) -2397.22
Earnings Per Share (EPS) -11.58
EBITDA -3.21
Effective Tax Rate (%) 21.93
Particulars SEP 2021 (Values in Cr)
Revenue 2.35
Operating Expense 45.42
Net Profit -33.61
Net Profit Margin (%) -1430.21
Earnings Per Share (EPS) -11.28
EBITDA -3.24
Effective Tax Rate (%) 21.92
Particulars JUN 2021 (Values in Cr)
Revenue 2.93
Operating Expense 44.00
Net Profit -32.04
Net Profit Margin (%) -1093.51
Earnings Per Share (EPS) -10.74
EBITDA -2.61
Effective Tax Rate (%) 21.97
Particulars MAR 2021 (Values in Cr)
Revenue 2.57
Operating Expense 35.96
Net Profit -24.84
Net Profit Margin (%) -966.53
Earnings Per Share (EPS) -8.33
EBITDA 3.42
Effective Tax Rate (%) 25.50
Particulars MAR 2022 (Values in Cr)
Revenue 8.50
Operating Expense 169.91
Net Profit -76.36
Net Profit Margin (%) -898.35
Earnings Per Share (EPS) -25.61
EBITDA 37.27
Effective Tax Rate (%) 30.01
Particulars MAR 2021 (Values in Cr)
Revenue 12.17
Operating Expense 166.71
Net Profit -121.71
Net Profit Margin (%) -1000.08
Earnings Per Share (EPS) -40.82
EBITDA -11.70
Effective Tax Rate (%) 21.20
Particulars MAR 2020 (Values in Cr)
Revenue 31.87
Operating Expense 173.85
Net Profit -114.07
Net Profit Margin (%) -357.92
Earnings Per Share (EPS) -38.26
EBITDA -14.41
Effective Tax Rate (%) 19.51
Particulars MAR 2019 (Values in Cr)
Revenue 32.03
Operating Expense 214.85
Net Profit -147.90
Net Profit Margin (%) -461.75
Earnings Per Share (EPS) -49.61
EBITDA -16.23
Effective Tax Rate (%) 18.46
Particulars MAR 2018 (Values in Cr)
Revenue 32.97
Operating Expense 153.71
Net Profit -96.09
Net Profit Margin (%) -291.44
Earnings Per Share (EPS) -32.24
EBITDA -14.49
Effective Tax Rate (%) 19.52
Particulars MAR 2021 (Values in Cr)
Book Value / Share -264.78
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -96.22
Particulars MAR 2020 (Values in Cr)
Book Value / Share -224.01
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -45.28
Particulars MAR 2019 (Values in Cr)
Book Value / Share -185.65
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -50.67
Particulars MAR 2018 (Values in Cr)
Book Value / Share -148.33
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 0.19
Particulars MAR 2017 (Values in Cr)
Book Value / Share -108.42
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -7.00
Particulars MAR 2021 (Values in Cr)
Book Value / Share -264.89
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -96.14
Particulars MAR 2020 (Values in Cr)
Book Value / Share -224.12
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -45.28
Particulars MAR 2019 (Values in Cr)
Book Value / Share -185.75
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -48.84
Particulars MAR 2018 (Values in Cr)
Book Value / Share -136.07
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -43.98
Particulars MAR 2017 (Values in Cr)
Book Value / Share -103.83
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -61.01
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.05
Total Assets 568.20
Total Liabilities 568.20
Total Equity -682.75
Share Outstanding 29816300
Price to Book Ratio -0.01
Return on Assets (%) -21.42
Return on Capital (%) 21.15
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.10
Total Assets 551.85
Total Liabilities 551.85
Total Equity -561.18
Share Outstanding 29816300
Price to Book Ratio -0.01
Return on Assets (%) -20.67
Return on Capital (%) 25.13
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 0.44
Total Assets 540.56
Total Liabilities 540.56
Total Equity -446.79
Share Outstanding 29816300
Price to Book Ratio -0.05
Return on Assets (%) -27.36
Return on Capital (%) 43.87
Particulars MAR 2018 (Values in Cr)
Cash & Short Term Investments 3.54
Total Assets 890.42
Total Liabilities 890.42
Total Equity -136.15
Share Outstanding 29816300
Price to Book Ratio -0.12
Return on Assets (%) -12.55
Return on Capital (%) -24.79
Particulars MAR 2017 (Values in Cr)
Cash & Short Term Investments 3.22
Total Assets 913.74
Total Liabilities 913.74
Total Equity -17.16
Share Outstanding 29816300
Price to Book Ratio -0.26
Return on Assets (%) -12.89
Return on Capital (%) -18.44
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.05
Total Assets 566.79
Total Liabilities 566.79
Total Equity -683.20
Share Outstanding 29816300
Price to Book Ratio -0.01
Return on Assets (%) -21.47
Return on Capital (%) 21.1
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.10
Total Assets 550.43
Total Liabilities 550.43
Total Equity -561.63
Share Outstanding 29816300
Price to Book Ratio -0.01
Return on Assets (%) -20.72
Return on Capital (%) 25.05
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 0.44
Total Assets 539.15
Total Liabilities 539.15
Total Equity -447.24
Share Outstanding 29816300
Price to Book Ratio -0.05
Return on Assets (%) -27.43
Return on Capital (%) 43.69
Particulars MAR 2018 (Values in Cr)
Cash & Short Term Investments 0.77
Total Assets 764.32
Total Liabilities 764.32
Total Equity -107.77
Share Outstanding 29816300
Price to Book Ratio -0.12
Return on Assets (%) -12.57
Return on Capital (%) -26.64
Particulars MAR 2017 (Values in Cr)
Cash & Short Term Investments 0.96
Total Assets 759.83
Total Liabilities 759.83
Total Equity -11.66
Share Outstanding 29816300
Price to Book Ratio -0.26
Return on Assets (%) -15.01
Return on Capital (%) -22.01
Particulars MAR 2021 (Values in Cr)
Net Income -154.47
Cash from Operations 125.32
Cash from Investing 0.06
Cash from Financing -125.43
Net change in Cash -0.05
Free Cash Flow 125.32
Particulars MAR 2020 (Values in Cr)
Net Income -141.73
Cash from Operations 112.36
Cash from Investing 0.07
Cash from Financing -112.42
Net change in Cash 0.01
Free Cash Flow 112.36
Particulars MAR 2019 (Values in Cr)
Net Income -181.39
Cash from Operations 456.05
Cash from Investing 96.57
Cash from Financing -573.59
Net change in Cash 0.01
Free Cash Flow 456.05
Particulars MAR 2015 (Values in Cr)
Net Income -85.95
Cash from Operations 79.90
Cash from Investing 3.05
Cash from Financing -9.86
Net change in Cash -5.15
Free Cash Flow 88.83
Particulars MAR 2014 (Values in Cr)
Net Income -93.99
Cash from Operations -53.53
Cash from Investing 32.55
Cash from Financing 25.38
Net change in Cash -2.25
Free Cash Flow 60.27
Particulars MAR 2021 (Values in Cr)
Net Income -154.47
Cash from Operations 125.32
Cash from Investing 0.06
Cash from Financing -125.43
Net change in Cash -0.05
Free Cash Flow 125.32
Particulars MAR 2020 (Values in Cr)
Net Income -141.73
Cash from Operations 112.36
Cash from Investing 0.07
Cash from Financing -112.43
Net change in Cash 0.01
Free Cash Flow 112.36
Particulars MAR 2019 (Values in Cr)
Net Income -181.39
Cash from Operations 455.78
Cash from Investing 0.09
Cash from Financing -455.79
Net change in Cash 0.08
Free Cash Flow 455.78
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

PARENTERAL DRUGS (INDIA) LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
3.39 4.62 redarrow
red-green-graph indicator
0 Bearish
0 Bullish
  • 5 Days 0.00
  • 26 Days 0.00
  • 10 Days 0.00
  • 50 Days 0.00
  • 12 Days 0.00
  • 100 Days 0.00
  • 20 Days 0.00
  • 200 Days 0.00
0.0 PIVOT

First Support

0.0

First Resistance

0.0

Second Support

0.0

Second Resistance

0.0

Third Support

0.0

Third Resistance

0.0

RSI

0.0

ADX

0.0

MACD

0.0

Williams % R

0.0

Commodity Channel Index (CCI)

0.0

Date

-

Week

0.0

Same Day

0.0

Month

0.0

1 Year

0.0

3 Year

0.0

Over 1 Month

9.70%

down

Over 1 Year

-19.47%

down

Over 3 Months

-15.67%

down

Over 3 Years

8.96%

down

Over 6 Months

-25.65%

down

Over 5 Years

-19.83%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

PARENTERAL DRUGS (INDIA) LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
26.7%
Promoter Holdings
73.28%
FII
0.0%
DII
0.0%
Promoter Shares(Pledge Percentage)
94.5%
Name Shares Category
Mvg Mercantile Private Limited 9722966.0 (32.61%) Shareholding of Promoter and Promoter Group
Rajratan Exports Private Limited 6666665.0 (22.36%) Shareholding of Promoter and Promoter Group
Pdpl Holdings Private Limited 3217120.0 (10.79%) Shareholding of Promoter and Promoter Group
Mahaganpati Investment Private Limited 1600000.0 (5.37%) Shareholding of Promoter and Promoter Group
Pdpl Securities Private Limited 611506.0 (2.05%) Shareholding of Promoter and Promoter Group
Shitiz Sehgal 417000.0 (1.4%) Public Shareholding
Amax Network Pvt Ltd 400000.0 (1.34%) Public Shareholding
Parenteral Commercial Services Private Limited 30986.0 (0.1%) Shareholding of Promoter and Promoter Group
Mr Anil Mittal 1600.0 (0.01%) Shareholding of Promoter and Promoter Group
Mr. Anil Mittal 266.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

PARENTERAL DRUGS (INDIA) LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
13 Sep 2010 2.0 Final 15 Sep 2010 Equity shares
23 Dec 2009 1.5 Final 25 Dec 2009 Equity shares
24 Sep 2008 1.5 Final 26 Sep 2008 Equity shares
21 Sep 2007 1.5 Final 25 Sep 2007 Equity shares
Ex-Date Ex-Bonus Ratio
15 Sep 2010 13 Sep 2010 1:3
05 Nov 2007 02 Nov 2007 1:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

PARENTERAL DRUGS (INDIA) LTD. Share Price

Parenteral Drugs (India) Limited was incorporated in 1983 as a private limited company. In 1989, the Company established their first unit to manufacture I V Fluids in Polypropylene containers with a capacity of 18 lakh bottles per annum. In March 1994, the company was converted into a public limited company.

Parenteral Drugs (India) is an India-based pharmaceutical company. The Company manufactures, and markets pharmaceutical products in India, including solid and liquid orals, such as antibiotics and anti-bacterial, anti-ulcerant, analgesics/anti-inflammatory, multivitamins and minerals, anxiolyic , antiprotozoal, anticold, anthelmintic, anti-histaminic, muscle relaxant, cardiac, antidiabetic, cough syrup, appetite enhancer and injections.

The Company produces various therapeutic segments of In-Vitro (I V) Fluids, such as electrolytes, antibacterial, energy replenisher, irrigation solution, osmotic diuretic, dialysis solution. They produce 400-milligram Ciprofloxacin infusion in 200 milliliter with 5% dextose. Apart from the single dose dispensers, the Company launched multi-dose eye/ ear drops in plastic containers. The dispensers are made using the form-fill-seal technology.

In September 1994, the Company came out with a Public Issue at a premium of Rs 80, aggregating Rs 7.03 crore, to part-finance their Rs 8.97 Cr. expansion. During the year 1994-95, the Company set up a joint venture unit in Ukraine for manufacture of a wide range of pharmaceuticals. In addition, they set up a unit for the manufacture of I V Fluids at Jalandhar in Punjab.

During the year 1997-98, the Company purchased 100% equity of the Parenteral Drugs International Ltd and made it a wholly owned subsidiary of the company. They also purchased 50% equity in Parental Drugs (Punjab) Ltd. During the year 1999-2000, the company was awarded ISO 9002 Certification as a symbol of quality products.

In 2003-04, the Company installed Injections with the production capacity of 516 lakh numbers. During the year 2005-06, the company increased the production capacity of I V Fluid Transfusion by 45,000,000 Nos to 120,000,000 Nos. In addition, it set up a plant for manufacturing pharmaceutical products at Baddi in Himachal Pradesh.

During the year 2006-07, the company increased the production capacity of Tablets/ Capsules by 1,125,000,000 Nos, Ampoules by 90,000,000 Nos and Injections 56,400,000 Nos. During the year 2007-08, they increased the production capacity of Large Volume by 30,000,000 Nos and Ampoules by 95,000,000 Nos.

In 2008-09, the Scheme of Amalgamation between M/s. PFL Holdings Private Limited and M/s. Goa Holdings (India) Private Limited with the Company was implemented and made effective. Resulting the amalgamation, M/s.Punjab Formulations Limited and M/s.Goa Formulations Limited became wholly-owned subsidiaries of the Company with effect from 1st November, 2008.

The Company incorporated a wholly-owned subsidiary in Kazakhstan in the name of 'Parenteral Drugs Kazakhstan' to undertake the business of manufacturing of pharmaceutical products during 2008. In 2009, the Company launched products comprised of Falcistar and Merogol for Injections and tablets/ capsules like Azimist and Megastar. It launched the products under the oncology (anti-cancer) segment comprising of Fludapar, Trexopar, Mindro and Ifoparwith Mesna.

During 2009-10, Company converted 12,00,000 warrants into equity shares of Rs. 10/-each, which were issued by way of preferential allotment on 24th August, 2009, which were allotted to M/s.Mahaganpati Investments Private Limited, a Company under Promoter Category.

During FY 2010-11, 10 new products such as GRASIPAR PFS, LEUCOPAR-50 INJECTION, PACOFF EXPECTORANT, PIDIMOL IV, 5 FU-PAR INJECTION, BOTEPAR INJECTION, ERLOPAR TABLETS, TEGNID INJECTION, CEFACE CV TABLETS, ERLOPAR TABLETS, ANTOXY-2 SYRUP and TAMOLGAN IV were introduced in the market.

In 2014, Punjab Formulations Limited, a wholly owned subsidiary ceased to be in existence as the said Company was amalgamated with Infutec Healthcare Limited (Formerly: Goa Formulations Limited), a wholly owned subsidiary of the Company w.e.f. 12 September, 2014 vide Order of the Honorable High Court of Bombay Judicature.

During year 2015-16, Company disinvested equity investment in two subsidiary companies namely Parentech Healthcare Limited and Parenteral Surgicals Limited. During 2016-2017, the Company disinvested from the equity shares held in its 2 subsidiary companies namely Abhay Drugs Limited and Anjaney Pharmaceuticals Limited.

During the year 2018-19, Infutec Healthcare Limited, an erstwhile wholly owned subsidiary, ceased to be a subsidiary of company w.e.f 10 July, 2018.

Parent organization Indian Private
NSE symbol PDPL
Founded 1983
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Parenteral Drugs (India) Ltd?

Answer Field

The share price of Parenteral Drugs (India) Ltd for NSE is ₹ 2.90 and for BSE is ₹ 3.39.

What is the Market Cap of Parenteral Drugs (India) Ltd?

Answer Field

The market cap of Parenteral Drugs (India) Ltd for NSE is ₹ 0.0 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Parenteral Drugs (India) Ltd?

Answer Field

The 52 Week High and Low of Parenteral Drugs (India) Ltd for NSE is ₹ 2.90 and ₹ 0.00 and for BSE is ₹ 3.39 and ₹ 0.00.

How to Buy Parenteral Drugs (India) Ltd share?

Answer Field

You can trade in Parenteral Drugs (India) Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Parenteral Drugs (India) Ltd?

Answer Field

The 1 year returns on the stock has been -19.47%.

What is the Current Share Price of Parenteral Drugs (India) Ltd?

Answer Field

Parenteral Drugs (India) Ltd share price is for NSE ₹ 2.90 & for BSE ₹ 3.39 as on Aug 21 2023 12:00 AM.

What is the Market Cap of Parenteral Drugs (India) Ltd Share?

Answer Field

The market cap of Parenteral Drugs (India) Ltd for NSE ₹ 0.0 & for BSE ₹ 0.0 as on Aug 21 2023 12:00 AM.

What is the P/E Ratio of Parenteral Drugs (India) Ltd Share?

Answer Field

As on Aug 21 2023 12:00 AM the price-to-earnings (PE) ratio for Parenteral Drugs (India) Ltd share is 0.0.

What is the PB ratio of Parenteral Drugs (India) Ltd Share?

Answer Field

As on Aug 21 2023 12:00 AM, the price-to-book (PB) ratio for Parenteral Drugs (India) Ltd share is 0.0.

How to Buy Parenteral Drugs (India) Ltd Share?

Answer Field

You can trade in Parenteral Drugs (India) Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Parenteral Drugs (India) Ltd Share on Bajaj Broking App?

Answer Field

To buy Parenteral Drugs (India) Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Parenteral Drugs (India) Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|